NuScale Power (NYSE: SMR) - Q4 & Full Year 2025 Earnings Deep Dive
2/28/26
SEQH Capital Research
NuScale Power (NYSE: SMR), Q4 & Full Year 2025 Earnings Deep Dive
Tear Sheet – February 28, 2026
Why This Report Exists
NuScale Power reported Q4 FY2025 results that materially missed consensus on both revenue and EPS, driven by the conclusion of a one-time engineering contract and a 507.4M dollar non-cash charge related to its ENTRA1 partnership. While the company fortified its balance sheet with over 1.2B dollars in capital raises during 2025, the underlying metrics reveal a pre-commercial company with high cash burn, significant shareholder dilution, and a commercial pipeline that remains entirely non-binding. This report analyzes the full financials and includes a comparative analysis against Nano Nuclear Energy (NNE).
Q4 & Full Year 2025 Financials
Revenue collapse:
Q4 2025 revenue: 1.81M dollars, a 94.7% decline from Q4 2024 and a 74.8% miss vs. consensus of 8.76M.
Full-year revenue: 31.5M dollars, down 15.0% from FY2024.
Revenue quality is low, with the vast majority from one-off engineering services and licensing fees (RoPower, Fluor). No diversified, recurring commercial revenue stream from end-user utilities.
The ENTRA1 effect:
507.4M dollar non-cash charge under Partnership Milestone Agreement (PMA) with ENTRA1, NuScale’s exclusive commercialization partner.
G&A expenses inflated 703% YoY to 609.8M dollars. Full-year operating loss: (689.6M dollars).
The milestone payment was 16 times larger than the entire year’s revenue, illustrating the high cost of the “asset-light” strategy.
Net loss and dilution:
Full-year net loss: (664.5M dollars), or (2.17 dollars) per share.
Share count grew 262% from end of 2024 to 337.9M shares outstanding at year-end 2025, driven by over 1.2B dollars in ATM equity offerings.
Balance Sheet & Liquidity
Total liquidity: ~1.25B dollars (836.4M cash + 417.8M short-term investments).
Post-ENTRA1 cash payment (~250M), effective liquidity position: ~1.0B dollars.
Management guided adjusted annual burn rate: 170M–200M dollars. Implied runway: 5–6 years.
Runway could be shortened by future ENTRA1 milestone payments.
Investment income (25.3M in FY2025) is nearly as large as operating revenue (31.5M). In Q4, interest income of 8.9M actually exceeded operating revenue of 1.81M, highlighting dependence on treasury operations over core business.
Strategic & Commercial Progress
NRC Standard Design Approval: NuScale is the only SMR technology provider to have received SDA from the NRC, a durable competitive advantage providing significant timing and de-risking edge over all competitors.
ENTRA1/TVA 6 GW Program:
Non-binding agreement between ENTRA1 and TVA to potentially deploy up to 6 GW of NuScale SMRs, the largest planned SMR deployment in the U.S.
Agreement remains entirely non-binding. Until firm PPAs are signed, this pipeline is aspirational.
Street consensus requires 100%+ revenue growth in FY2027, entirely dependent on converting non-binding frameworks into contracted, revenue-generating projects.
NuScale (SMR) vs. Nano Nuclear (NNE)
Capital efficiency: NNE’s cash represents over 52% of market cap with negligible liabilities. NuScale’s cash is larger in absolute terms but smaller relative to market cap and burdened by significant liabilities.
Cash burn: NNE annualized burn ~36M vs. NuScale’s adjusted ~200M, providing significantly more runway and optionality per dollar of market cap.
Dilution: NNE has maintained a tight share structure while NuScale has aggressively diluted shareholders to fund operations.
Valuation
121.7x EV/Sales on FY2025 revenue, one of the most expensive pre-commercial stocks in the market.
Valuation prices in significant future success that has not yet been contractually secured.
Compression to a more reasonable multiple requires converting pipeline into binding revenue.
Key Risks
Lack of binding commercial contracts, pipeline is entirely non-binding and aspirational.
Execution risk concentrated with partner ENTRA1, not directly controlled by NuScale.
High probability of future dilution to fund operations and partnership milestones.
Unresolved material weakness in financial reporting.
Cash runway could be shortened by ENTRA1 milestone payment obligations.
Revenue quality concern, no recurring commercial revenue stream from utilities.
SEQH View
NuScale is a company of dualities. It possesses the invaluable asset of NRC design certification and a massive pipeline, yet it is burdened by a high-cost partnership structure, a dilutive funding strategy, and a lack of binding commercial agreements. The company has built a war chest of cash, but operational performance has yet to justify a 121.7x EV/Sales premium valuation. For investors seeking advanced nuclear exposure, the superior balance sheet efficiency, lower cash burn, and differentiated market focus of competitors like Nano Nuclear may present a more capital-efficient and less dilutive path to participating in the nuclear renaissance.
Want the Full Q4 & FY2025 Earnings Deep Dive?
[READ THE COMPLETE NUSCALE EARNINGS ANALYSIS]
The full report includes institutional-grade financial analysis and competitive benchmarking unavailable elsewhere:
Complete income statement breakdown with ENTRA1 PMA charge decomposition and G&A expense forensics
Revenue quality analysis separating one-off engineering/licensing fees from recurring commercial revenue
Balance sheet transformation walkthrough with pre- and post-ENTRA1 payment liquidity modeling
Cash burn and runway projections under multiple scenarios including future milestone payment risk
Investment income vs. operating revenue analysis exposing treasury dependence over core business
ENTRA1/TVA 6 GW pipeline probability-weighted valuation with scenario analysis on binding contract conversion
Head-to-head NuScale (SMR) vs. Nano Nuclear (NNE) comparative analysis: capital efficiency, cash burn, dilution, and qualitative scorecard
Share count dilution timeline from SPAC merger through 262% expansion with per-share metric compression analysis
121.7x EV/Sales valuation contextualization and what revenue milestones are required to justify the premium
Risk matrix covering binding contract dependency, ENTRA1 concentration, material weakness, and dilution trajectory
NuScale holds the only NRC-approved SMR design in the world, but is the market paying 121x sales for a pipeline that’s entirely non-binding? This report gives you the financial forensics to decide.
Available exclusively to SEQH Capital Research paid subscribers. Upgrade to access →
